Serum resistin and the risk for hepatocellular carcinoma in diabetic patients  

作　　者：Mona Mohamed Ibrahim Abdalla 

机构地区：[1]Department of Human Biology,School of Medicine,International Medical University,Bukit Jalil 57000,Kuala Lumpur,Malaysia

出　　处：《World Journal of Gastroenterology》2023年第27期4271-4288,共18页世界胃肠病学杂志（英文版）

摘　　要：Hepatocellular carcinoma(HCC),the predominant type of liver cancer,is a major contributor to cancer-related fatalities across the globe.Diabetes has been identified as a significant risk factor for HCC,with recent research indicating that the hormone resistin could be involved in the onset and advancement of HCC in diabetic individuals.Resistin is a hormone that is known to be involved in inflammation and insulin resistance.Patients with HCC have been observed to exhibit increased resistin levels,which could be correlated with more severe disease stages and unfavourable prognoses.Nevertheless,the exact processes through which resistin influences the development and progression of HCC in diabetic patients remain unclear.This article aims to examine the existing literature on the possible use of resistin levels as a biomarker for HCC development and monitoring.Furthermore,it reviews the possible pathways of HCC initiation due to elevated resistin and offers new perspectives on comprehending the fundamen-tal mechanisms of HCC in diabetic patients.Gaining a better understanding of these processes may yield valuable insights into HCC’s development and progression,as well as identify possible avenues for prevention and therapy.

关 键 词：Hepatocellular carcinoma RESISTIN Insulin resistance OBESITY DIABETES Liver cancer 

分 类 号：R587.1[医药卫生—内分泌] R735.7[医药卫生—内科学]